Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
TMX Group completes acquisition of Cboe Australia from Cboe Global Markets

TMX Group completes acquisition of Cboe Australia from Cboe Global Markets

ReutersReuters2026/08/02 21:01
  • TMX Group completed its acquisition of Middlebury Holdings, the operator of Cboe Australia, from Cboe Global Markets.
  • The exchange will be rebranded as TMX Australia Exchange.
  • The deal expands TMX’s presence in Australia, adding an exchange platform spanning listings, ETFs, structured products, warrants, and trading services.
  • Cboe Australia recently received a license for corporate listings, supporting TMX’s push to grow its global listings franchise.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TMX Group Limited published the original content used to generate this news brief via Newsfile (Ref. ID: 202608021700NEWSFILECNPR____20260802_307507_1) on August 02, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

GSK (GSK.US) strengthens its oncology pipeline with acquisition worth up to $750 million for EnmuBio's trispecific TCE, targeting multiple myeloma

GlaxoSmithKline announced on Tuesday that it has reached an agreement with Chinese biotechnology company ImmuneOnco to acquire the global rights to one of the latter’s trispecific T-cell engagers (TCE) for a total transaction amount of up to $750 million.

智通财经2026/09/15 08:06
GSK (GSK.US) strengthens its oncology pipeline with acquisition worth up to $750 million for EnmuBio's trispecific TCE, targeting multiple myeloma